Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …

Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-
prone HIV-1 replication leads to the production of drug-resistant viral variants …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the
prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the …

Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …

Combination antiretroviral therapy (ART) is highly effective in controlling human
immunodeficiency virus (HIV)-1 but requires lifelong medication due to the existence of a …

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to
rapid viral rebound. Here we report the results of a phase IIa open label clinical trial …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range
of viral isolates in vitro and protect non-human primates against infection,. Previous work …